Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share (QNRX)
CUSIP: 74907L409
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share
- Shares outstanding
- 843,913
- Total 13F shares
- 1,720
- Share change
- -364
- Total reported value
- $11,352
- Price per share
- $6.60
- Number of holders
- 1
- Value change
- -$2,402
- Number of sells
- 1
Quarterly Holders Quick Answers
What is CUSIP 74907L409?
CUSIP 74907L409 identifies QNRX - Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Previous quarter: Q4 2025
Recent filing periods for CUSIP 74907L409:
Top shareholders of QNRX - Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Stonepine Capital Management, LLC |
3/4/5
13D/G
13F
|
10%+ Owner · Company |
11%
from 13D/G
|
3,271,100
|
$47,201,973 | — | 26 Mar 2026 | |
| Woodline Partners LP |
13D/G
13F
|
Company |
9.5%
|
2,785,370
|
$38,298,838 | $0 | 31 Dec 2025 | |
| INTEGRATED CORE STRATEGIES (US) LLC |
13D/G
|
— |
4.6%
|
2,618,595
|
$36,005,681 | +$9,858,888 | 31 Dec 2025 | |
| ARMISTICE CAPITAL, LLC |
13D/G
|
— |
5%
|
1,081,183
|
$7,049,313 | $0 | 31 Mar 2025 | |
| Ikarian Capital, LLC |
13F
13D/G
|
Company |
13%
from 13D/G
|
211,538
|
$3,052,493 | — | 31 Dec 2025 | |
| Aberdeen Group plc |
13D/G
13F
|
Company |
8.9%
|
75,000
|
$1,082,250 | $0 | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
8.9%
|
74,817
|
$1,079,609 | — | 31 Dec 2025 | |
| SummitTX Capital, L.P. |
13F
|
Company |
7.7%
|
64,795
|
$934,992 | — | 31 Dec 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
7.1%
|
59,838
|
$863,462 | — | 31 Dec 2025 | |
| ADAR1 Capital Management, LLC |
13F
13D/G
|
Company |
6.9%
from 13D/G
|
58,230
|
$840,259 | — | 31 Dec 2025 | |
| AIGH Capital Management LLC |
13F
|
Company |
5.8%
|
49,323
|
$711,731 | — | 31 Dec 2025 | |
| Resolute Capital Asset Partners LLC |
13D/G
13F
|
Company |
8.5%
|
50,000
|
$671,000 | $0 | 10 Oct 2025 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
3%
|
25,000
|
$360,750 | — | 31 Dec 2025 | |
| Simplify Asset Management Inc. |
13F
|
Company |
2.1%
|
17,448
|
$251,775 | — | 31 Dec 2025 | |
| Denise P. Carter |
13D/G
3/4/5
|
Denise Carter · Chief Operating Officer, Director |
4.9%
|
939,238
|
$244,202 | +$82,374 | 27 Jan 2025 | |
| Michael Myers |
13D/G
3/4/5
|
Chief Executive Officer, Director |
4.9%
|
939,230
|
$244,200 | +$82,331 | 27 Jan 2025 | |
| Centiva Capital, LP |
13F
|
Company |
1.4%
|
12,053
|
$173,925 | — | 31 Dec 2025 | |
| Dennis Langer |
3/4/5
|
Director |
—
mixed-class rows
|
97,470
mixed-class rows
|
$128,648 | +$128,640 | 04 Feb 2026 | |
| Gordon Dunn |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
734,513
mixed-class rows
|
$67,985 | — | 23 Dec 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.36%
|
3,000
|
$43,290 | — | 31 Dec 2025 | |
| GAMMA Investing LLC |
13F
|
Company |
0.25%
|
2,084
|
$30,072 | — | 31 Dec 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.2%
|
1,666
|
$24,031 | — | 31 Dec 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0.03%
|
247
|
$3,564 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
17
|
$245 | — | 31 Dec 2025 | |
| Sally Bridget Lawlor |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
85,690
mixed-class rows
|
— | — | 04 Feb 2026 | |
| Anthony James Culverwell |
3/4/5
|
Director |
—
class O/S missing
|
21,709
|
— | — | 04 Feb 2026 | |
| Natalie Ee Mun Leong |
3/4/5
|
Director |
—
class O/S missing
|
12,211
|
— | — | 04 Feb 2026 | |
| Joseph Patrick Cooper |
3/4/5
|
Director |
—
class O/S missing
|
8,141
|
— | — | 04 Feb 2026 | |
| Sember Michael T. |
3/4/5
|
Director |
—
class O/S missing
|
8,141
|
— | — | 04 Feb 2026 |
Institutional Holders of Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share (QNRX) as of Q1 2026
As of 31 Mar 2026,
Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share (QNRX) was held by
1 institutional
shareholder
that filed Form 13F with the SEC.
Together, they reported ownership of
1,720 shares.
The largest 1 holders included
GAMMA Investing LLC.
This page lists
1
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
18
Q1 2026 holders
1
Holder diff
-17
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.